Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do we know anything about what Andrew Patient was doing between his resignation from Merus Labs in July 2016 and being hired by IPCI back in September this year, 2017? I could not find anything.
Patient received a grant of options:
Nov 2/17
Oct 20/17
Patient, Andrew
Direct Ownership
Options 50 - Grant of options 60,000
https://www.canadianinsider.com/company?menu_tickersearch=Intellipharmaceutics%20International%20Inc.%20%7C%20I
AngeloFoca and ImpactTrader16 did you meet in Las Vegas?
So, Steve Boyd is one party that took part in the direct offering. So,who got the 2M+ shares left.
There is no connection between Cerecor und IPCI, except Steve Boyd. And I don't think a merger or something like that is a possibility! I also do not see any benefit of a merger. I think we should look closer at Steve Boyd and his hedge fund Armistice: As we can see with Cerecor, he can become quiet active as an investor. I would be very happy, to have him as a future board member. The next thing I will check, when I find the time for it: Has he forced management changes in companies, he invested? Is there hope, he will put the needed pressure on the Odidis?
No, Boyd is not founder of cerecor, but of Armistice (his hedge fund). And yes, hopefully now there is finally an "activist" who gives the Odidis directions. But I would not be overly optimistic. Just have a look how the share price of cerecor acted since he is one of the directors.
Steven Boyd is not the CEO of Cerecor, but he is one of their directors. See https://www.cerecor.com/about/board-of-directors
Thanks for your reply, my question is more about the value of the Indian tender. Some people on agoracom are very excited about it - honestly me too, because it would revive the GaAs platform. But noone really can give an idea, what the value of this tender could be. So when you wrote, it may push the share price back to old heights, I wondered what you think, the price tag of the tender is.
So why a e-petition? A simple private letter signed by a bunch of shareholders with a lot of shares should do the same! The importance is to gain support of some people with a lot of shares, showing power! A public e-petition will just hurt the company and the share price.
Why do we not simply wait, whether Samsa will be get his court case against IPCI? Everything you ask for, I think, is also wanted by Samsa and he already did the right steps!
You wrote "POETF may even run to $2 or $3 if a deal with India's government is announced for the GA's" - you have any reason to come up with those numbers? I am trying to find out the value of the tender, but don't find anymore than pure speculations.
When will they report next earning?
Weird there is no premarket activity. Also the Ask and Bid seems weird! Anyone has L2 data? What is happening?
The story of Sarepta's drug Duchenne is different to the Rexista adcom, but still an interesting read about an overruled adcom:
Sarepta: FDA Policy Forced AdCom To Vote Against Patients' Interests
FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy
ImpactTrader16, I read some of your posts on stocktwits. Your wrote there, that they found already a new CFO and at the same time you write that a buyout is coming. How does one fit to the other? Also the buyout rumour posted there on stockwits was published again on one of these pages, that everyone can publih anything - like the last buyout rumours, that turned out to be misonformation.
Hi Samsa,
any news about the Purdue ligitation?
Where/when did he say it?
Where did IPCI use the expression "Plug & Play" to speak about Rexista? It sound more like a fitting expression for PODRAS.
Thanks for the info. Is the first meeting in front of the judge still on the 26th?
Purdue Pharma L.P. et al v. Intellipharmaceutics International Inc. et al
Just found the complaint online: see https://insight.rpxcorp.com/litigation_documents/12406652
"Intellipharmaceutics International Inc. (the “Company”, “Intellipharmaceutics”, “we”, “us” or “our” ) may offer and issue from time to time common shares of the Company (“common shares”), preference shares of the Company (“preference shares”), warrants to purchase common shares or preference shares (“warrants”), subscription receipts (“subscription receipts”), subscription rights (“subscription rights”) and/or units comprised of one or more of the foregoing (“units” and together with the common shares, preference shares, warrants, subscription receipts and subscription rights, the “securities”) or any combination thereof for up to an aggregate initial offering price of U.S.$100,000,000 (or the equivalent thereof in other currencies) during the period that the registration statement of which this short form base shelf prospectus (the “prospectus”), including any amendments hereto, forms a part remains effective. Any offerings of the Company’s securities in Canada pursuant to this prospectus and any related filings with the securities commissions or other securities regulatory bodies in Canada shall be made only during the 25-month period commencing on the date hereof. Securities may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of sale and set forth in an accompanying prospectus supplement (a “prospectus supplement”)."
"I feel, based on the history and the facts as presented, he will grant IPCI's request to lift the FDA stay which will allow the approval to continue, but then let the case play out. "
Would that mean, IPCI could get a final approval or just a tentative approval if the PDUFA wants to approve Rexista?
Is there a realistic chance, that the judge will rule against Purdue on the 26th of July?
Samsa, anything new about the lawsuit?
Legal question: Can the FDA hold an Adcom with the ongoing patent litigation?
Is there a connection between Amin Talati & Upadhye and IPCI?
Okay, thanks. So I am verz happy about any information that you think is important and that you can share with us. From your experience: If I understand correctly Purdue ist sueing, claiming that Rexista is a generic - but IPCI claims also filled a NDA. Is this kind of lawsuit typical in the pharma industry?
If IPCI is sueing them, isn't that material news, that they need to publish?
Is IPCI answer anywhere available online?
A small article I found about Pristiq - IPCI waits for the final approval of a generic vesion, that they partnered with MNK. The article talks about Pfizer and the market:
"Pfizer faces a challenging year on the patent loss front, starting with the generics of its antidepressant Pristiq now hitting the market.
Mylan today said it had launched its copycat of desvenlafaxine extended-release tablets, in 50 mg and 100 mg doses. India’s Lupin also has its version on the market and a slew of other generic makers, including Sandoz and Teva’s new Actavis unit, have approvals.
Pfizer has estimated it will have about $578 million at risk this year, but Mylan, citing IMS Health data, pointed out that the drug brought in $853 million for the 12 months through January 2017.
Pristiq itself was a drug launched to protect Pfizer sales from the patent loss on a preceding antidepressant, Effexor. Pristiq was first developed by Wyeth before it merged into Pfizer in 2009 to create the drug giant it is today." See http://www.fiercepharma.com/pharma/pfizer-faces-first-2017-patent-loss-as-pristiq-generics-crash-party
mmh, now I also dont find the approval in the Orange Book anymore. Very weird!
True, but it also showed up yesterday in the list of new approvals. Weird, that someone erased it again.
The approval for IPCIs Seroquel is not listed anymore on the FDA homepage. Boths approvals for IPCI and Lupin just disappeared: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page
Fully agree, MNK has a much better standing in the US. So I don+t worry, that IPCI will capture a very meaninful market share and will get a nice cash flow from it! Just I never heard of Lupin befor, so I wanted to point out, who is the competitor, that enters the market parallel with IPCI.
Heavy competition for IPCI/MNK. Yesterday also Lupin Ltd received the final approval for Seroquel:
"Lupin Limited is a transnational pharmaceutical company based in Mumbai. It is the seventh-largest company by market capitalization; and the 10th-largest generic pharmaceutical company by revenue globally.Lupin is the fifth-largest generic pharmaceutical company in the US by prescription-led market share and 3rd largest Indian pharmaceutical company by revenue. It has the distinction of being the fastest growing generic pharmaceutical player in the US[16] and Japan;,and is the 4th largest and the fastest growing generic pharmaceutical player in South Africa." (Source: Wikipedia).
Thanks a lot for this explanation!
We all the time just talk about the patent litigation by Purdue against Rexista. But what about Rhodes Technologies and Grünenthal GmbH do they have a strong case against IPCI?